23 September 2020>: Clinical Research
Gamma Knife Radiosurgery (GKRS) for Patients with Prolactinomas: Long-Term Results From a Single-Center Experience
Yanli Li 1AEG* , Minyi Huang 2BCD* , Shunyao Liang 2BC* , Chao Peng 3CDE , Xi Li 4BCD , Jiamin Zeng 5CD , Yong He 2BF , Wangen Li 1EF , Yinhui Deng 2ADG , Jinxiu Yu 2BCE*DOI: 10.12659/MSM.924884
Med Sci Monit 2020; 26:e924884
Table 1 Patient baseline characteristics of pre-GKRS and GKRS parameters.
Characteristic | Value |
---|---|
Male/Female, n (%) | 5/19 (20.8/79.2) |
Median age, (range), years | 30.5 (18.1–51.1) |
Median follow-up time, (range), months | 109.3 (23.2–269.3) |
Median tumor volume, (range), cm | 0.716 (0.019–6.535) |
Tumor size, n (%) | |
Microadenoma | 10 (41.7) |
Macroadenoma | 13 (54.2) |
Giant adenoma | 1 (4.2) |
Indication for GKRS | |
Resistance to DA | 20 (83.3) |
Drug intolerance | 4 (16.7) |
Type of DAs | |
Bromocriptine | 22 (91.7) |
Cabergoline | 2 (8.3) |
Suprasellar extension, n (%) | 6 (25) |
Cavernous sinus invasion, n (%) | 4 (16.7) |
pre-GKRS | |
DAs treatment, n (%) | 24 (100) |
Surgical resection, n (%) | 3 (12.5) |
Hypopituitarism prior to GKRS, n (%) | 16 (66.7) |
Gonadotrophin deficiency | 15 (62.5) |
ACTH deficiency | 1 (4.2) |
TSH deficiency | 5 (20.8) |
Visual function, n (%) | |
Normal | 20 (83.3) |
Visual dysfunction* | 4 (16.7) |
Cranial nerve dysfunction of pre-GKRS, n (%) | 0 |
Median margin dose, (range), Gy | 15 (10.5–23.6) |
Median maximum dose, (range), Gy | 33.2 (24–66.6) |
Median isodose level, (range), (%) | 40 (30–60) |
GKRS – gamma knife radiosurgery; ACTH – adrenocorticotropic hormone; TSH – thyroid-stimulating hormone; DAs – dopamine agonist. * Visual dysfunction consisted of visual field defect and/or visual acuity decrease. |